Humacyte

HUMANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$163.901 M

$0.59 +0.75%

Close of 21 Sept 2026

Revenue

$2.04M

#3414 by revenue

Earnings

-$40.8M

Loss-making

Shares outstanding

277,798,105

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#102Precision BiosciencesDTIL$179.4M
#103Outlook TherapeuticsOTLK$167.1M
#104HumacyteHUMA$163.9M
#105Armata PharmaceuticalsARMP$158.4M
#106Tenaya TherapeuticsTNYA$151.1M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Humacyte, worth $24.8K. Grants and option exercises are excluded.

Keith Anthony Jones$6.93K
10,000 shares at $0.69 on 20 Aug 2026 · filed 21 Aug 2026
Keith Anthony Jones$17.8K
30,000 shares at $0.59 on 17 Aug 2026 · filed 19 Aug 2026

What if Humacyte were worth as much as…

Open the what-if tool →

Gold $30.3T

$108,978.62

Per share 184,710× higher

Bitcoin $1.72T

$6,190.84

Per share 10,493× higher

Nvidia $5.48T

$19,726.05

Per share 33,434× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Humacyte are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.